The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Triple Negative Breast Neoplasms Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02539017
• Other study ID #: Renyu-012
• Status: Withdrawn
• Phase: Phase 2
• First received: August 5, 2015
• Last updated: August 9, 2016
• Start date: November 2015

Study information

• Verified date: August 2016
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

As a special type of breast cancer, the triple negative breast cancer has the characteristics of high recurrence rate (2 years after surgery), high distant metastasis rate, poor prognosis and short survival time. No matter at home or abroad, the clinical researches of the triple negative breast cancer are mainly focused on finding new drugs and new treatment strategies in order to reduce its recurrence and distant metastasis rate. The DC/CIK cell immunotherapy combined with chemotherapy in the clinical study of metastatic triple negative breast cancer has already confirmed benefit. This study is based on the theory that the optimal timing of cellular immunity is while the host tumor load is under the smallest state. Put forward the hypothesis that the DC/CIK cell immunotherapy combined with chemotherapy may improve the disease-free survival and overall surviva after the triple negative breast cancer operation. The investigators intends to use the RCT, observing the clinical significance of cellular immune adjuvant therapy of triple negative breast cancer in 340 patients with TNBC. Do the safety evaluation of cellular immunity in the adjuvant treatment of breast cancer treatment, explore the clinical strategies for breast cancer immunotherapy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age: =18 years old

• ECOG score: =1

• the Primary invasive ductal carcinoma which are during the Ib period to IIIc and should be surgical resection while no distant metastasis (except for the tumor of N3 in the internal mammary region, the above clavicle LN), and the diagnosis of the tumor was confirmed by pathological diagnosis;

• There must be no residual in the surgical margin(except lobular carcinoma in situ), and the remove number of axillary lymph nodes in the same side must be above 10 (except for the negative sentinel lymph nodes).

• Have the results of the immunohistochemical detection of ER, PR and HER2, the one whose HER2+ and HER2++ should be confirmed by FISH.

• The chemotherapy regimens recommended by the guide and radiation therapy (qualified).

• Have normal tissue and organ function:

Bone marrow function: ANC must be=1.5×109/L, the platelet count must be=100×109/L , hemoglobin must be =10g/dL.

Renal function: serum creatinine must be=1.5ULN Liver function: total bilirubin =1.5ULN,AST=1.5ULN,ALT=1.5ULN

• The results of imaging examination of the contralateral breast molybdenum, chest CT, abdominal B ultrasound and whole body bone scan should be required before the random.

• Sign the informed consent form.

• Have a good compliance, and can be follow-up for at least 5 years.

Exclusion Criteria:

• have the past history of breast cancer with the same or opposite side, a history of immune system diseases.

• T1aN0M0, inflammatory breast cancer and bilateral breast cancer; patients with T cell lymphoma.

• Have the history of other malignant tumors before (except for the cervical carcinoma in situ, squamous cell carcinoma of the skin, skin basal cell carcinoma).

• Have the important organ dysfunction of heart, lung, liver, kidney and others.

• People who are pregnant or unwilling to use contraception during treatment.

• Patients who have received organ transplantation or long-term use of immunosuppressive agents.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Chemo
Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles

Biological:
• Immunotherapy
Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell

Locations

Country	Name	City	State
China	the First Affiliated Hospital of Xi 'an Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease free survival		up to 3 years	Yes
Secondary	overall survival		up to 3 years	Yes
Secondary	percentage of participants with fever, skin rash, bone marrow suppression, allergy, gastrointestinal response, myalgia and arthralgia		up to 3 years	Yes